Lakewood Capital managing partner Anthony Bozza sent his quarterly letter to investors today, and like most of the rest of the hedge fund industry, Q1 2018 was a difficult one. However, the firm still had several new ideas to present to investors.
ValueWalk obtained and reviewed the Lakewood Capital Q1 2018 letter, and among Lakewood's new ideas for the first quarter were two significant new short positions: Ligand Pharmaceuticals and iRhythm Technologies.
Lakewood Capital Still Shorting Tesla Motors Inc, SolarCity Corp
First a...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
